Publications by authors named "J Saez-Penataro"
Enhancing our comprehension of mRNA vaccines may facilitate the future design of novel vaccines aimed at augmenting immune protection while minimising reactogenic responses. Before this design is carried out, it is important to determine whether adaptive immunity correlates with the reactogenicity profile of vaccines. We studied a large cohort that was vaccinated with mRNA vaccines to answer this question.
View Article and Find Full Text PDFArticle Synopsis
- - The study aimed to analyze adverse events (AEs) linked to apalutamide treatment in prostate cancer patients and evaluate the effectiveness of a multidisciplinary team (MDT) approach in managing these AEs in a real-world hospital setting.
- - Out of 121 patients treated, over half experienced AEs, with a notable difference in dose interruptions and treatment discontinuation between those managed with and without the MDT protocol; only 16.7% had interruptions under MDT compared to 24.5% without it.
- - The findings indicate that employing a multidisciplinary team was significantly beneficial in reducing the risk of treatment discontinuation due to AEs, emphasizing the need for coordinated care in managing patient treatment.
Purpose: B-cell maturation antigen (BCMA)-chimeric antigen receptor T-cells (CART) improve results obtained with conventional therapy in the treatment of relapsed/refractory multiple myeloma. However, the high demand and expensive costs associated with CART therapy might prove unsustainable for health systems. Academic CARTs could potentially overcome these issues.
View Article and Find Full Text PDFPurpose: In order to explore clinical pharmacology and therapeutics (CPT) teaching and practices across continental Europe, the European Association of Clinical Pharmacology and Therapeutics (EACPT) made a survey in 2022 amongst its 27 affiliated societies.
Methods: The survey was made available online to EACPT representatives, and 47 filled-in questionnaires were received from 25 countries (one to five per country), representing all geographic areas of Europe.
Results: Clinical pharmacologists (CPs) spend 25%, 30%, 15%, and 25% of their time in teaching, hospital activities, committees, and research, respectively, with large variations across and within countries.
Advanced therapy medicinal products (ATMPs) are becoming the new kid on the block for the treatment of a variety of indications with promising results. Despite the academic contribution to the basic and clinical research of ATMPs, undertaking a full product development process is extraordinarily challenging and demanding for academic institutions. Meeting regulatory requirements is probably the most challenging aspect of academic development, considering the limited experience and resources compared with pharmaceutical companies.
View Article and Find Full Text PDF